Celldex Therapeutics releases Q2 2026 results update

Celldex Therapeutics, Inc. states that on August 6, 2026 it issued a press release announcing its financial results for the second quarter of 2026.

Rhea-AI Filing Summary

Celldex Therapeutics, Inc. states that on August 6, 2026 it issued a press release announcing its financial results for the second quarter of 2026. The press release is provided as Exhibit 99.1 and is treated as information that is furnished, rather than filed, under the Exchange Act, limiting its treatment under Section 18 and other liability provisions.

The company also identifies Exhibit 104 as the cover page interactive data file embedded within the Inline XBRL document. Any future use of the press release in Securities Act or Exchange Act reports will occur only if specifically incorporated by reference.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

Key Terms

Section 18 of the Securities Exchange Act of 1934, incorporated by reference, Inline XBRL, Emerging growth company

4 terms

Section 18 of the Securities Exchange Act of 1934 regulatory

"for purposes of Section 18 of the Securities Exchange Act of 1934, as amended"

incorporated by reference regulatory

"nor shall such information be deemed incorporated by reference in any filing"

Inline XBRL technical

"Cover Page Interactive Data File (embedded within the Inline XBRL document)"

Inline XBRL is a file format for financial filings that embeds machine-readable data tags directly inside the human-readable report, so the same document can be read by people and parsed by software. For investors it makes extracting, comparing and verifying financial numbers faster and more reliable—like a grocery list where each item also has a barcode—reducing manual errors and speeding up analysis.

Emerging growth company regulatory

"Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

Earnings Snapshot

second quarter of 2026

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Celldex Therapeutics (CLDX) announce on August 6, 2026?

Celldex Therapeutics announced that on August 6, 2026 it issued a press release with financial results for the second quarter of 2026. The release is included as Exhibit 99.1 and is provided as furnished information rather than as a filed document.

How did Celldex Therapeutics (CLDX) communicate its Q2 2026 financial results?

Celldex Therapeutics communicated its Q2 2026 financial results through a press release furnished as Exhibit 99.1. That exhibit forms part of a current report and is designated as furnished, which affects how it is treated under Exchange Act liability provisions.

Which reporting period do the latest Celldex Therapeutics (CLDX) results cover?

The latest results disclosed by Celldex Therapeutics cover the second quarter of 2026. This period is specified in the description of the press release, which the company identifies as announcing its financial results for that quarter.

How is the Celldex Therapeutics (CLDX) earnings press release treated under the Exchange Act?

The earnings press release is treated as furnished, not filed, under the Exchange Act. The company states it is not deemed filed for Section 18 purposes and is not incorporated by reference into Securities Act or Exchange Act filings unless specifically referenced.

What exhibits accompany Celldex Therapeutics (CLDX)’s August 6, 2026 current report?

The company lists two exhibits: Exhibit 99.1, a press release dated August 6, 2026 with second-quarter 2026 financial results, and Exhibit 104, the cover page interactive data file embedded within the Inline XBRL document.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/06/2026 - 04:02 PM Accepted by SEC EDGAR 08/06/2026 - 04:01 PM Learn about SEC filing dates

False000074421800007442182026-08-062026-08-06iso4217:USDxbrli:sharesiso4217:USDxbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_________________

FORM 8-K

_________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  August 6, 2026

_______________________________

Celldex Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

_______________________________

Delaware	000-15006	13-3191702
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

Perryville III Building, 53 Frontage Road, Suite 220

Hampton, New Jersey 08827

(Address of Principal Executive Offices) (Zip Code)

(908) 200-7500

(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

_______________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $.001	CLDX	Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On August 6, 2026, Celldex Therapeutics, Inc. (the "Company") issued a press release announcing its financial results for the second quarter of 2026. The full text of the press release is furnished as Exhibit 99.1 hereto and is incorporated by reference herein.

The information in this Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits
99.1	Press Release of Celldex Therapeutics, Inc., dated August 6, 2026.
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Celldex Therapeutics, Inc.
Date: August 6, 2026	By:	/s/ Sam Martin
		Sam Martin
		Senior Vice President and Chief Financial Officer

Filing Exhibits & Attachments

5 documents

Press Releases

• EX-99.1 PRESS RELEASE 68.6 KB

Other Documents

• EX-101 XBRL SCHEMA FILE 3.3 KB
• EX-101 XBRL DEFINITION FILE 25.5 KB
• EX-101 XBRL LABEL FILE 35.1 KB
• EX-101 XBRL PRESENTATION FILE 24.1 KB